Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 1999

View Archived Issues

Abbott: Q1 1999 highlights

Genelabs and SmithKline Beecham share DARPA grant for drug development

GnRH pharmaccine reduces testosterone to castration levels

AVI confirms that classic approaches valid for testing antisense compound

Efficacy of IL-2 Gene Medicine is enhanced by combination with chemotherapeutic agent

News from FASEB: CT-3 is a potent and long-acting analgesic with good tolerability

Phytopharm reports preliminary phase IIa results for P-54 in osteoarthritis

Novavax estrogen cream completes phase II trial

Oxazolidinones useful for resistant Gram-positive infections

Abarelix depot is safe and effective in patients with endometriosis

Inhibitors of PTKs and T-cell activation/proliferation in development at BMS

Shiseido provides methods of promoting hair regrowth

Aminomethyl benzofuran-based compounds as potent and selective 5-HT1A receptor ligands

Novel cytotoxic agent from Nippon Steel with potential in inflammation and osteoporosis

Taro evaluates anticonvulsant barbiturate compounds in dog model

Merck identifies a nonpeptide, linearly minimized, centrally constrained gpIIb/IIIa antagonist

News from FASEB: novel factor Xa inhibitor presented by DuPont Pharmaceuticals

Fujisawa, Quark collaborate on genomics research in the area of stroke

Amoxil cleared for b.i.d. dosing in children

Immunization strategy effectively blocks the behavioral effects of cocaine in monkeys

TerraGen raises financing, changes name to reflect expanded capabilities

Progen's heparanase inhibitor prevents restenosis in experimental model

Nabi nicotine vaccine shows promise in preclinical studies

Monsanto responds to press publication of Celebrex adverse events

PNU-159548 undergoes phase I trials; preclinical results presented at AACR meeting

TP-508 promotes the wound-healing process via a novel mechanism

Promising phase I/II data for 81C6 pave the way for phase III trials in brain tumor patients

Favorable efficacy and safety profile of CEP-701 in PDAC

Extensive preclinical evaluation establishes potential of novel antitumor agent --CHS-828

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...